Aligos Therapeutics
ALGS
40 hedge funds and large institutions have $26.2M invested in Aligos Therapeutics in 2025 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
21% more funds holding
Funds holding: 33 → 40 (+7)
1% more capital invested
Capital invested by funds: $26M → $26.2M (+$208K)
3.87% less ownership
Funds ownership: 49.55% → 45.68% (-3.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$2.53M |
| 2 |
SC
SummitTX Capital
Fort Worth,
Texas
|
+$1.32M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
+$672K |
| 4 |
Two Sigma Investments
New York
|
+$393K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$392K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Readystate Asset Management
Chicago,
Illinois
|
-$1.99M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$1.69M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.37M |
| 4 |
Squarepoint
New York
|
-$299K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$149K |
ALGS Hedge Fund Activity: Q4 2025 in Review
40 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q4 2025, worth a combined $26.2M — up 0.8% from $26M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ALGS positions and 5 closed out — a net gain of 7 holders — while 9 added to existing stakes and 7 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $2.53M. The largest seller was Readystate Asset Management, exiting entirely with an estimated $1.99M sold.
- 40 institutional investors held Aligos Therapeutics (ALGS) as of Q4 2025, up from 33 in Q3 2025.
- Funds reported $26.2M of Aligos Therapeutics stock for Q4 2025, up 0.8% quarter-over-quarter.
- 12 funds opened new Aligos Therapeutics positions in Q4 2025 and 5 closed out, a net change of +7 holders.
- The largest Aligos Therapeutics buyer in Q4 2025 was Marshall Wace, an estimated $2.53M added.
- The largest Aligos Therapeutics seller in Q4 2025 was Readystate Asset Management, an estimated $1.99M sold.
Based on aggregated 13F filings for Q4 2025.